Amgen (NASDAQ:AMGN) Stock Sale Revealed by Rep. David Taylor

Key Points

• Rep. David Taylor disclosed selling $1,001–$15,000 of Amgen stock on November 3 from a trust-linked retirement account.
• Amgen reported quarterly earnings of $6.45 per share, beating the $5.79 consensus estimate; revenue of $10.37 billion also exceeded forecasts and rose 8.5% year over year.
• Amgen announced a quarterly dividend of $2.52 per share, equivalent to $10.08 annually and a stated yield of 2.2%; analysts’ consensus rating was Hold.

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on November 3rd. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 11/5/2026.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 11/5/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 11/5/2026.
• Purchased $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 11/5/2026.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 11/3/2026.
• Purchased $1,001 - $15,000 in shares of Eaton NYSE: ETN on 11/3/2026.
• Sold $1,001 - $15,000 in shares of Kroger NYSE: KR on 11/3/2026.
• Purchased $1,001 - $15,000 in shares of AT&T NYSE: T on 11/3/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 11/3/2026.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 11/3/2026.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $465.67 on Friday. The firm has a 50 day simple moving average of $425.31 and a 200 day simple moving average of $381.17. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business's quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the company posted $5.64 EPS. Research analysts predict that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen's dividend payout ratio is 58.47%.

Hedge Funds Weigh In On Amgen

Several hedge funds and other institutional investors have recently modified their holdings of the company. Oxford Financial Group LTD. LLC increased its position in shares of Amgen by 9.3% during the third quarter. Oxford Financial Group LTD. LLC now owns 823 shares of the medical research company's stock worth $347,000 after acquiring an additional 70 shares during the period. Octavia Wealth Advisors LLC increased its stake in Amgen by 95.1% in the third quarter. Octavia Wealth Advisors LLC now owns 2,332 shares of the medical research company's stock valued at $983,000 after purchasing an additional 1,137 shares during the last quarter. Empowered Funds LLC lifted its position in Amgen by 40.4% in the third quarter. Empowered Funds LLC now owns 134,668 shares of the medical research company's stock valued at $56,764,000 after acquiring an additional 38,761 shares during the last quarter. United Southern Bank Trust Department acquired a new position in Amgen during the third quarter worth approximately $1,318,000. Finally, Kovack Advisors Inc. boosted its stake in Amgen by 9.0% during the 3rd quarter. Kovack Advisors Inc. now owns 4,801 shares of the medical research company's stock worth $1,999,000 after purchasing an additional 395 shares during the period. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AMGN. Wells Fargo & Company boosted their target price on Amgen from $430.00 to $460.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 4th. Weiss Ratings raised shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 8th. Royal Bank Of Canada raised their price objective on shares of Amgen from $430.00 to $470.00 and gave the company an "outperform" rating in a research report on Wednesday, November 4th. Cantor Fitzgerald boosted their target price on Amgen from $440.00 to $465.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Finally, Freedom Broker lowered shares of Amgen from a "buy" rating to a "hold" rating and upped their target price for the stock from $450.00 to $470.00 in a research report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $424.66.

Amgen News Summary

Here's some of the latest news about AMGN:

• Positive Sentiment: Amgen said dazodalibep met key endpoints in a Phase 3 Sjögren’s disease trial, advancing the case for the drug as a potential future growth driver. Jefferies analysts said caveated comparisons suggest its efficacy may look stronger than Novartis’ registrational treatment. Article Article
• Positive Sentiment: Argus raised its price target to $515 from $460 and maintained a buy rating, signaling further upside in its view. Article
• Neutral Sentiment: A comparison of Amgen and Vertex highlights Amgen’s broad global footprint and diversified medicines portfolio, but offers no clear near-term catalyst for the shares. Article

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.